Supplementary Figure 4 from A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer by Matthew T. Campbell (15096440)

“…<p>Flow cytometry of immune cells from serially collected blood samples with evidence of significant decrease in circulating NK cells in: A) Metastatic renal cell carcinoma cohort. …”

Supplementary Material for: Endoscopic Anti-reflux Mucosal Interventions for Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis of Efficacy, Safety, and Compara... by figshare admin karger (2628495)

“…Results: Technical success was 100%, with a mean procedure time of 42.09 minutes. ARMIs significantly reduced the proportion of patients using PPI (RR=2.22-3.06; <3–24 months; P≤0.001) and improved GERD-Q, GERD-HRQL, and DeMeester scores through 36 months (P<0.05). …”

<b><i>Escherichia coli α-hemolysin induces red blood cell retention in a microfluidic spleen-like device</i></b> by Nicolas Saffioti (9965939)

“…</a></p><p dir="ltr">The second device, which simulates the RBCs’ filtration by the spleen’s red pulp, revealed that HlyA, but not ProHlyA, increased RBCs’ retention in small gaps resembling splenic fenestrations. …”

Table 1_Has carbon finance been able to promote clean energy development? — a low-carbon technology innovation perspective.xlsx by Rui Cui (622759)

“…It is found that carbon finance significantly promotes clean energy development, but this contribution decreases with the intervention of low-carbon technology innovation. …”

Changes in cytokine production over the second week of culture. by Nils Ågren (21474419)

“…The decrease in IFN-γ production between days 9 and 14 was significant in all groups. …”

Tobacco and alcohol use are the risk factors responsible for the greatest burden of head and neck cancers: a study from the Global Burden of Disease Study 2019 by Yue Yuan (113839)

“…Our findings revealed that smoking posed a significantly greater risk for laryngeal and lip and oral cavity cancers, whereas alcohol consumption was more strongly linked to NPC. …”

Table 1_Characteristics and trends of unintentional injuries among children and adolescents in Kunshan, China: a hospital-based retrospective study, 2018–2023.docx by Li Shen (110858)

“…Unintentional injury cases decreased significantly during COVID-19 (2020–2022). …”

Additional file 16 of Recombination and transposition drive genomic structural variation potentially impacting life history traits in a host-generalist fungal plant pathogen by Mark C. Derbyshire (5841785)

“…Red cells are for test statistics that indicate a decrease in SV impact on phenotype.…”

Microbial Alliances: Unveiling the Effects of a Bacterial and Fungal Cross-Kingdom SynCom on Bacterial Dynamics, Rhizosphere Metabolites, and Soybean Resilience in Acidic Soils by Zhongling Wen (13878743)

“…RhRi also enhanced soil enzyme activity (urease, phosphatases), which resulted in an increase in nitrogen and phosphorus availability and a decrease in rhizosphere toxicity. These alterations enhanced plant resilience, soil structure, and microbial diversity. …”

Table 1_A low-protein soybean-free diet improves carcass traits and meat quality and modulates the colonic microbiota in Daweizi pigs.docx by Haohua Fu (20675654)

“…In addition, the LPNS diet significantly increased leanness and decreased the fat-skin rate and bone rate of Daweizi pigs. …”

Data Sheet 1_Detection of hemodynamic changes in a porcine lipopolysaccharide model of systemic inflammation using dynamic light scattering measurements of the microcirculation.pdf by Louwrina H. te Nijenhuis (20762678)

“…Both intervention groups showed a Hurst exponent decrease centrally at T2 and peripherally already at T1.…”

Supplementary Material for: Preliminary efficacy, tolerability, and safety analysis of Darolutamide for metastatic castration‑resistant prostate cancer: a single-center, open-label... by Yu J. (3610580)

“…The median time to PSA50 in the Darolutamide group was 1.5 months (95%CI 0.2619- 0.9545), significantly lower than that in the placebo group (3.0 months [95%CI 1.048- 3.818], p= 0.0259); The median time to PSA90 in the experimental group was 4 months (95%CI 0.3094- 1.437), 2 months shorter than that in the placebo group (6.0 months [95%CI 0.6961- 3.232]).With the median follow-up of 6 months, , the median decrease in serum PSA was -81.8% (range -60.4 to -99.9%) in the Darolutamide group and -69.4% (range -50.3 to -89.6%) in the placebo group. …”

Image1_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image2_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image8_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image5_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image6_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image3_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image4_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”

Image7_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

“…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m² per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”